Search Results - "Joung, J.Y."

The dual effects of Maillard reaction and enzymatic hydrolysis on the antioxidant activity of milk proteins by Oh, N S, Lee, H A, Lee, J Y, Joung, J Y, Lee, K B, Kim, Y, Lee, K W, Kim, S H

“…The objective of this study was to determine the enhanced effects on the biological characteristics and antioxidant activity of milk proteins by the…”
Get more information

Strong correlation between glycaemic variability and total glucose exposure in type 2 diabetes is limited to subjects with satisfactory glycaemic control by Suh, S, Joung, J.Y, Jin, S.M, Kim, M.Y, Bae, J.C, Park, H.D, Lee, M.S, Lee, M.K, Kim, J.H

“…Abstract Aims This study investigated the relationship between markers of overall glucose exposure, postprandial glucose excursions and glycaemic variability…”
Get full text

A prospective evaluation of conventional cystography for detection of urine leakage at the vesicourethral anastomosis site after radical prostatectomy based on computed tomography by Han, K.S, Choi, H.J, Jung, D.C, Park, S, Cho, K.S, Joung, J.Y, Seo, H.K, Chung, J, Lee, K.H

“…Aim To evaluate the diagnostic accuracy of conventional cystography for the detection of urine leakage at the vesicourethral anastomosis (VUA) site after…”
Get full text

The insignificant effect of the androgen deprivation therapy on the incidence of dementia in a retrospective population-based prostate cancer study using the extension of Cox proportional hazard model with time-dependent survival by Kim, S.H., Joung, J.Y., Kim, S-H., Kim, Y.A., Yang, M.S., Back, J.H.

Get full text

1817P A phase I/II efficacy and safety study of LAE001/prednisone and afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following 1-3 lines of standard of care by Diamond, E., Kwak, C., Orr, D., Bamidele, A., Jeong, I.G., Bessudo, A., Dunshee, C., Henderson, S., Joung, J.Y., Lee, S., Chaves, J., Slater, D., Patnaik, A., Pieczonka, C., Lee, W., Choi, Y.D., Guo, P., Ma, K., Cao, E., Yue, Y.

Get full text

1811P Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study by Fay, A.P., Fizazi, K., Matsubara, N., Azad, A.A., Saad, F., De Giorgi, U.F.F., Joung, J.Y., Fong, P.C., Jones, R.J., Zschäbitz, S., Oldenburg, J., Shore, N.D., Dunshee, C., Carles Galceran, J., Cislo, P., Chang, J., Healy, C.G., Niyazov, A., Agarwal, N.

Get full text

1812P Exploration of germline (g) vs somatic (s) origin of homologous recombination repair (HRR) gene alterations and potential associations with antitumor activity in the HRR-deficient population from TALAPRO-2 by Yip, S.M., Fizazi, K., Matsubara, N., Azad, A.A., Joung, J.Y., Fong, P.C., Carles Galceran, J., De Giorgi, U.F.F., Jones, R.J., Liu, G., Fay, A.P., Voog, E., Zschäbitz, S., Oldenburg, J., Di Santo, N., Healy, C.G., Lin, X., Laird, D., Agarwal, N.

Get full text

1805P Efficacy of olaparib (ola) + abiraterone (abi) vs placebo (pbo) + abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial by Mehra, N., Clarke, N.W., Armstrong, A.J., Oya, M., Shore, N.D., Procopio, G., Guedes, J.D.C., Arslan, C., Parnis, F., Brown, E., Schlürmann, F., Joung, J.Y., Sugimoto, M., Choi, Y.D., Castellano, D., Urun, Y., Hosius, C., Desai, C., Degboe, A., Saad, F.

Get full text

The comparison of prognoses between radiotherapy and radical prostatectomy in patients with high risk localized or locally advanced prostate cancer treated with neoadjuvant hormonal therapy by Joung, J.Y, Kim, S.H, Seo, H.K, Chung, J, Cho, K.H, Park, W.S, Lee, K.H

Get full text

Risk prediction model for prostate cancer in a Korean population by Joung, J.Y, Kim, S, Kwon, W.-A, Lee, K.H, Nam, B.-H

Get full text

Prognostic significance of nephrectomy in patients with metastatic renal cell carcinoma treated with first-line systemic therapy: A 10-year retrospective analysis according to MSKCC and Heng risk criteria by Seung Ok, S.O, Joung, J.Y, Seo, H.K, Lee, K.H, Chung, J, Kim, S.H

Get full text

A1160 - PROpel: Efficacy of abiraterone + olaparib vs. abiraterone + placebo in the first-line treatment of patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) at baseline by Clarke, N.W., Armstrong, A.J., Thiery-Vuillemin, A., Oya, M., Shore, N., Procopio, G., Guedes, J.D., Arslan, C., Mehra, N., Parnis, F., Brown, E., Schlürmann, F., Joung, J.Y., Sugimoto, M., Sartor, O., Poehlein, C., Barker, L., Degboe, A., Saad, F.

Get full text

PROpel: Efficacy of abiraterone + olaparib vs. abiraterone + placebo in the first-line treatment of patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) at baseline by Clarke, N.W., Armstrong, A.J., Thiery-Vuillemin, A., Oya, M., Shore, N., Procopio, G., Guedes, J.D., Arslan, C., Mehra, N., Parnis, F., Brown, E., Schlürmann, F., Joung, J.Y., Sugimoto, M., Sartor, O., Poehlein, C., Barker, L., Degboe, A., Saad, F.

Get full text

Dose prior surgical experience matter to robot-assisted radical prostatectomy beginner? Comparative analysis of outcomes of initial 100 cases performed by senior and junior surgeon by Kwon, W-A, Kim, S.H, Seo, H.K, Chung, J, Lee, K.H, Joung, J.Y

Get full text

Positive surgical margin is a big distress to robot-assisted radical prostatectomy beginner: Results of Initial 100 cases performed by single surgeon by Kwon, W-A, Kim, S.H, Seo, H.K, Chung, J, Lee, K.H, Joung, J.Y

Get full text

1807P Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status by Matsubara, N., Fizazi, K., Azad, A.A., Carles Galceran, J., Fay, A.P., De Giorgi, U.F.F., Joung, J.Y., Fong, P.C., Voog, E., Jones, R.J., Shore, N.D., Dunshee, C., Zschäbitz, S., Karsh, L.I., Barthelemy, P., Lin, X., Healy, C.G., Di Santo, N., Zohren, F., Agarwal, N.

Get full text

752 Prognostic significance of nephrectomy in patients with metastatic renal cell carcinoma treated with first-line systemic therapy: A 10-year retrospective analysis according to MSKCC and Heng risk criteria by Joung, J.Y, Seo, H.K, Kim, S.H, Lee, K.H, Chung, J, Kwon, W-A

Get full text

608P Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC) by Chung, B.H., Huang, J., Uemura, H., Choi, Y.D., Ye, Z., Suzuki, H., Kang, T.W., He, D., Joung, J.Y., Brookman-May, S.D., McCarthy, S., Bhaumik, A., He, J., Mundle, S.D., Chowdhury, S., Agarwal, N., Ye, D., Chi, K.N., Uemura, H.

Get full text

157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) by Oya, M., Armstrong, A.J., Thiery-Vuillemin, A., Shore, N., Procopio, G., Arslan, Ç., Mehra, N., Parnis, F., Brown, E., Constans Schlurmann, F., Joung, J.Y., Sugimoto, M., Sartor, O., Liu, Y-Z., Poehlein, C.H., Desai, C., Del Rosario, P.M.D., Clarke, N., Saad, F.

Get full text

1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) by Saad, F., Armstrong, A.J., Thiery-Vuillemin, A., Oya, M., Shore, N.D., Procopio, G., Arslan, C., Mehra, N., Parnis, F., Brown, E., Constans Schlurmann, F., Joung, J.Y., Sugimoto, M., Sartor, O., Liu, Y-Z., Poehlein, C.H., Desai, C., Del Rosario, P.M.D., Clarke, N.

Get full text